Abstract
For Antimitochondrial antibodies (AMA) testing, both indirect immunofluorescense (IF) and ELISA (M2) are currently used. Herein we aimed to suggest which is better for AMA testing in clinical setting. Recent nation-wide surveillances for PBC demonstrated that AMA testing with M2 has been prevailed instead of IF. On the other hand, 3-5% of PBC patients had M2-negative but IF-positive AMA, and these patients might not be diagnosed as PBC if only M2 would have been tested. In another PBC cohort at our hospital we failed to detect any difference between patients with only IF-positive and those with M2-positive. Therefore, M2 should be used for screening for AMA, and if M2 was negative AMA should be reexamined with IF.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
